Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a clinical-stage biotechnology company whose news flow centers on the development of its Decoy bacterial immunotherapy platform for cancer and viral infections. The company’s updates frequently highlight progress in its clinical program for Decoy20, its lead candidate, as well as financing transactions and corporate developments disclosed through press releases and SEC filings.
Investors following INDP news can expect detailed reports on the INDP-D101 clinical trial, including the monotherapy evaluation of Decoy20 and the combination arm with the PD-1 checkpoint inhibitor tislelizumab in advanced solid tumors. Recent announcements have described safety lead-in results, individual patient responses such as a partial response in a urothelial cancer patient, and instances of stable disease in combination cohorts, along with commentary from company leadership on trial strategy and next steps.
Indaptus also issues news about scientific presentations and conference participation, where its team discusses how the Decoy platform activates innate and adaptive immune cells and its potential to support allogeneic cell therapies by enhancing donor cell potency. In addition, the company regularly reports quarterly financial results, outlining research and development spending on its Phase 1/1b/2 program, general and administrative expenses, cash runway expectations, and the impact of financings such as private placements of convertible notes, equity offerings and preferred stock transactions.
For market participants, the INDP news stream offers insight into clinical milestones, safety and early efficacy signals, intellectual property developments, capital structure changes, reverse stock split implementation, and board and management updates. Monitoring this page provides a consolidated view of how Indaptus is advancing its Decoy platform and managing the operational and financial aspects of its clinical-stage business.
Indaptus Therapeutics (Nasdaq: INDP) announced that the American Association for Cancer Research (AACR) accepted its abstract for presentation at the annual scientific conference from April 14-19, 2023, in Orlando. The poster, titled “A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy,” will be presented by Michael J. Newman, Ph.D., on April 18, 2023. Indaptus focuses on innovative therapeutics leveraging a Decoy anti-tumor platform that activates immune responses safely via intravenous delivery. This technology shows promise in treating various cancers and chronic infections.
Indaptus Therapeutics (Nasdaq: INDP) announced the addition of Emory Winship Cancer Institute as a clinical trial site for its Phase 1 trial of INDP-D101, a treatment targeting advanced solid tumors. This open-label study aims to assess the safety, tolerability, and pharmacokinetics of Decoy20, the company’s lead compound. Emory's participation indicates validation of Decoy20’s scientific concepts and the urgent need for treatment options in this area. The trial will enroll patients who have exhausted standard therapies, with initial data anticipated as sites are activated.
Indaptus Therapeutics has initiated the first human dosing in its Phase 1 clinical trial of Decoy20, aimed at treating advanced solid tumors. The initial subject reported expected, manageable side effects linked to immune activation, which aligns with Indaptus' therapeutic hypothesis. This trial will evaluate the safety, tolerability, and pharmacokinetics of Decoy20, with further subjects expected to be enrolled soon. The primary endpoint focuses on the incidence and severity of adverse events, with important secondary endpoints including response rates and immunological effects.
Indaptus Therapeutics (Nasdaq: INDP) has appointed Dr. Robert Martell to its Board of Directors. Dr. Martell brings over 20 years of experience in the pharmaceutical industry, previously serving as Head of Research and Development at Curis, Inc. His extensive background includes roles in both publicly traded and private companies, as well as significant positions at major firms like Bayer and Bristol-Meyers Squibb. The Company aims to leverage Dr. Martell's expertise in drug development and oncology to advance its clinical programs, particularly those using its Decoy platform for cancer treatments.
Indaptus Therapeutics (Nasdaq: INDP) has announced the addition of Morristown Medical Center as a new clinical trial site for its Phase 1 trial of INDP-D101, a treatment for advanced solid tumors. Patient screening is expected to begin soon. The trial aims to assess the safety, tolerability, and pharmacokinetics of Decoy20, the company's lead compound. The expansion of trial sites is expected to expedite patient enrollment, aiding in gathering initial data. Indaptus believes Decoy20 has the potential to innovate solid tumor treatments, with ongoing studies showing promising pre-clinical results against various carcinomas.
Indaptus Therapeutics (Nasdaq: INDP) has initiated its first-in-human Phase 1 clinical trial, INDP-D101, evaluating Decoy20 for patients with advanced solid tumors. The trial commenced at USC Norris Cancer Center, aiming to assess safety, tolerability, and pharmacokinetics of Decoy20. The study will determine the maximum tolerated dose and investigate its clinical activity. Encouraged by preclinical data, Indaptus aims to advance to the trial's expansion phase following dose determination. Initial cohort results are expected in 2023.
Indaptus Therapeutics (Nasdaq: INDP) has reported its Q3 2022 financial results and is on track to initiate a Phase 1 clinical trial of Decoy20 for treating solid tumors in Q4 2022. The FDA cleared the IND application for this trial, aimed at evaluating Decoy20's safety and efficacy. In Q3 2022, R&D expenses rose to $1.6 million, while general and administrative expenses decreased to $2.0 million. The company holds approximately $28.5 million in cash and expects to fund operations into Q2 2024 without additional financing.
Indaptus Therapeutics announced that CEO Jeffrey A. Meckler will present at the LD Micro Main Event XV from October 25-27, 2022, at the Luxe Sunset Boulevard Hotel in Los Angeles. The presentation is scheduled for October 25 at 3:30 PM PT (Track 3). Interested parties can register to watch the presentation online. Indaptus focuses on immunotherapy, leveraging patented technology to activate immune responses against tumors and chronic viral infections. The company aims to develop innovative therapies and will hold one-on-one meetings during the conference.
Indaptus Therapeutics (Nasdaq: INDP) announced its CEO, Jeffrey A. Meckler, will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference on September 12, 2022, at 2:00 PM ET. The event will be held at the Lotte New York Palace Hotel from September 12 to 14. A live webcast will be available on the company’s website, with a replay accessible for 90 days after the event. Management will also hold one-on-one meetings post-conference. Details for registration and additional information can be found in the press release.
Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey A. Meckler will present a corporate overview at the JMP Securities Life Sciences Conference on June 16, 2022, at 2:30 p.m. ET in New York City. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 90 days post-event.
Indaptus specializes in immunotherapy, focusing on innovative solutions for cancer and viral infections. Their patented technology aims to activate immune responses through intravenous administration of non-pathogenic bacteria, showing promise in pre-clinical trials for various cancers and chronic viral infections.